DCC-2036 (Rebastinib) 化学構造
分子量: 553.59



Quality Control & MSDS


  • Compare Bcr-Abl Inhibitors
  • 研究分野
  • Combination Therapy
  • DCC-2036 (Rebastinib)のメカニズム



情報 DCC-2036 (Rebastinib)は、Abl1とT315I Abl1の構造的な支配阻害剤で、IC50 がそれぞれ 0.8 nM と 4 nMです。
目標 u-Abl1native p-Abl1native Abl1H396P u-Abl1T315I p-Abl1T315I
IC50 0.8 nM 2 nM 1.4 nM 5 nM 4 nM [1]
In vitro試験 DCC-2036 shows the potent inhibitory activities against purified native Abl1 in unphosphorylated (u-Abl1native) and phosphorylated (p-Abl1native) forms, unphosphorylated and phosphorylated gatekeeper mutant Abl1T315I, and the activation loop mutant Abl1H396P in a non-ATP-competitive manner with IC50 of 0.8 nM, 2 nM, 1.4 nM, 5 nM, and 4 nM, respectively. Moreover, DCC-2036 also inhibits the Src family kinases Src, LYN, FGR, and HCK, and the receptor TKs KDR, FLT3, and TIE2 with IC50 of 34 nM, 29 nM, 38 nM, 40 nM, 4 nM, 2 nM and 6 nM, respectively. [1] DCC-2036 shows the anti-proliferative activities against Ba/F3 cells expressing native or mutant Bcr-Abl1 with IC50 ranging from 2 nM to 150 nM. In addition, DCC-2036 also inhibits proliferation of the Ph+ cell line K562 (IC50 5.5 nM), and induces apoptosis in both Bcr-Abl1-expressing Ba/F3 and K562 cells potently. [1] A recent study shows that DCC-2036 shows the selectivity for growth inhibition of Bcr-Abl-positive cells by its marked inhibition of CML cell lines compared to non-CML leukemia lines. [2]
In vivo試験 In a mouse allograft model bearing Ba/F3-Bcr-Abl1T315I leukemia cells, DCC-2036 treatment by oral gavage at 100 mg/kg once daily effectively inhibits Bcr-Abl1 signaling and significantly prolongs mouse survival. [1]
臨床試験 DCC-2036 is currently in Phase I/II clinical trials in patients with chronic myeloid leukemia.
特集 A conformational control inhibitor of Abl1 and T315I Abl1.

推薦された実験操作 (公開の文献だけ)

キナーゼアッセイ: [1]

Assay of Abl1 kinase isoforms and determination of inhibitor potency Activity of u-Abl1native is determined by following the production of ADP from the kinase reaction through coupling with the pyruvate kinase/lactate dehydrogenase system. In this assay, the oxidation of NADH (measured as a decreased A340nm) is continuously monitored spectrophotometrically. The final reaction mixture (100 μL, in a 384-well Corning plate) is prepared as follows: An Abl1 kinase/coupled assay components mixture is prepared containing u-Abl1 kinase (1 nM), Abltide (EAIYAAPFAKKK, 0.2 mM), MgCl2 (9 mM), pyruvate kinase (~ 4 units), lactate dehydrogenase (~ 0.7 units), phosphoenol pyruvate (1 mM), and NADH (0.28 mM) in 90 mM Tris containing 0.1 % octyl-glucoside and 1 % DMSO, pH 7.5. Separately, an inhibitor mixture is prepared containing DCC-2036 serially diluted 3-fold in DMSO followed by dilution into buffer composed of 180 mM Tris, pH 7.5, containing MgCl2 (18 mM) and 0.2 % octyl-glucoside. Fifty μL of the inhibitor mixture is mixed with 50 μL of the above Abl1 kinase/coupled assay components mixture, which is then incubated at 30 °C for 2 hours before 2 μL of 25 mM ATP (500 μM, final) is added to start the reaction. The reaction is recorded every 2 minutes for 2.5 hours at 30 °C on a Polarstar Optima or Synergy2 plate reader. Reaction rate (slope) is calculated using the 1 to 2 hour time frame with reader's software. Percent inhibition is obtained by comparison of reaction rate with that of a DMSO control. IC50 values are calculated from a series of percent inhibition values determined at a range of inhibitor concentrations using GraphPad Prism. The kinase assay for Abl1T315I, p-Abl1native or Abl1H396P is assayed the same as above except that 2.2 nM Abl1T315I, 1 nM p-Abl1 native or 1.3 nM Abl1H396P is used. The above assay format is also used for kinases other than Abl1 with the exception of TIE2, for which a fluorescence polarization/Transcreener format is used. The assay conditions are the same as described above except that PolyE4Y (final 1 mg/mL) is used as the substrate and one hour preincubation is used.

細胞アッセイ: [1]

細胞系 Ba/F3 cells and primary Ph+ leukemia cells
濃度 0-10 μM
処理時間 72 hours
方法 Ba/F3 cells or primary Ph+ leukemia cells are plated in triplicate in 96-well plates containing test compounds. After 72 hours, viable cells are quantified by Resazurin or MTT assay. Cells are diluted in medium to be added to each well of a 96-well tissue culture-treated plate. All cells are incubated overnight and maintained in a humidified atmosphere at 37 °C and 5% CO2. Cells are treated the following day. Serum-free medium is used during treatment with DCC-2036. MTT is used to assess the viability of cells following treatment. Aliquots of 20 mL of stock MTT solution are added to each well containing 200 mL of medium (10% final solution) and incubated with the cells for 2 hours. Following incubation the medium is removed and 200 mL of dimethylsulfoxide added to solubilize the formazan crystals. The absorbance is read on the plate reader at 550 and 690 nm. A subtraction analysis of the dual wavelength is performed (D550 to D690) to increase accuracy of the measuremen

動物実験: [1]

動物モデル Ba/F3 cells transformed to interleukin-3 independence by transduction with either Bcr-Abl1native or Bcr-Abl1T315I retrovirus are injected intravenously into syngeneic Balb/c mice.
製剤 DCC-2036 is dissolved in 0.5% CMC/1% Tween-80.
投薬量 ≤100 mg/kg
管理 Administered via p.o.
Solubility 0.5% CMC/0.25% Tween 80 16 mg/mL
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesBaboonDogMonkeyRabbitGuinea pigRatHamsterMouse
Weight (kg)121031.
Body Surface Area (m2)
Km factor202012128653
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)



Download DCC-2036 (Rebastinib) SDF
分子量 553.59


CAS No. 1020172-07-9
保管 2年-20℃
6月-80℃in DMSO
溶解度 (25°C) * In vitro DMSO 111 mg/mL (200.5 mM)
<1 mg/mL (<1 mM)
エタノール 16 mg/mL (28.9 mM)
In vivo 0.5% CMC/0.25% Tween 80 16 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 1-(3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea


カスタマーレビュー (2)

Click to enlarge
Source PLoS One, 2013, 8, e73059. DCC-2036 (Rebastinib) purchased from Selleck
Method Immunoblot analysis
Cell Lines BaF3-T674I cells
Concentrations 0-200 nM
Incubation Time 36 h
Results Tyrosine kinase inhibitor sorafenib was effective for imatinib-resistant FIP1L1-PDGFRα T674I mutation cells, we also compared the inhibitory effect of DCC-2036 with sorafenib in the BaF3-T674I cells. It's found that DCC-2036 decreased the phosphorylated-PDGFRα with lower concentrations than sorafenib, indicating that DCC-2036 might be more potent.

Click to enlarge
Source PLoS One, 2013, 8, e73059. DCC-2036 (Rebastinib) purchased from Selleck
Method Immunohistochemical analysis
Cell Lines nude mice
Concentrations 200 mg/kg
Incubation Time 13 d
Results Immunohistochemical analysis with Ki67 (to measure cellproliferation) staining showed that DCC-2036 suppressed theproliferation of BaF3 cells harboring FIP1L1-PDGFRα T674Imutant in vivo.

製品表彰状 (2)



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related Bcr-Abl 阻害剤

  • PD173955

    PD173955 is a potent Bcr-Abl inhibitor with IC50 of 1-2 nM, also inhibiting Src activity with IC50 of 22 nM.

  • GNF-5

    GNF-5 is a selective and allosteric Bcr-Abl inhibitor in cells, without inhibition of cell-free abl kinase activity.

  • BAY 87-2243

    BAY 87-2243 is a potent and selective hypoxia-inducible factor-1 (HIF-1) inhibitor. Phase 1.

  • WH-4-023

    WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2nM and 6 nM, respectively.

  • Imatinib Mesylate (STI571)

    Imatinib Mesylate (STI571) は口でImatinibの生物学的利用能メシラート塩です。そして、それは v-Ablc-KitPDGFRのマルチターゲット阻害剤で、IC50 がそれぞれ 0.6 μM、 0.1 μM、 0.1 μMです。

  • Nilotinib (AMN-107)

    Nilotinib (AMN-107)は、30nM未満のIC50によるBcr-Abl阻害剤です。

    Features:A selective inhibitor of native and mutant Bcr-Abl.

  • Bafetinib (INNO-406)


    Features:Dual Bcr-Abl/Lyn inhibitor.

  • Ponatinib (AP24534)

    Ponatinib (AP24534) は、PI3KγとPI4KIIIβの新しくて強力な阻害剤で、IC50 がそれぞれ16 nM と 19 nMになる。

  • Degrasyn (WP1130)

    Degrasyn (WP1130)は、選択的な非ユビキチンアーゼ(DUB)阻害剤です。WP1130は、5人のダブズを妨げます:USP5、UCH-L1、USP9x、USP14とUCH37。

    Features:WP1130 has an advantage over imatinib mesylate in that its activity is not inhibited by a variety of Abl kinase mutations, including T315I.


Tags: DCC-2036 (Rebastinib)を買う | DCC-2036 (Rebastinib)供給者 | DCC-2036 (Rebastinib)を購入する | DCC-2036 (Rebastinib)費用 | DCC-2036 (Rebastinib)生産者 | オーダーDCC-2036 (Rebastinib) | DCC-2036 (Rebastinib)代理店